A new study published in Movement Disorders is adding to growing scientific interest in the relationship between the gut microbiome and neurological conditions such as Parkinson’s disease.
The research investigated the effects of Symprove, the multi-strain live and active bacteria supplement, on gut microbiota composition, inflammatory markers and symptoms in people living with Parkinson’s disease.
Gastrointestinal symptoms are among the most common non-motor features of Parkinson’s disease and can significantly affect quality of life. Increasingly, scientists are exploring how disruptions in the gut microbiome may be linked to inflammation, constipation, and motor and non-motor symptoms for people with the condition.
In this randomised, double-blind, placebo-controlled trial, 74 adults with Parkinson’s disease and constipation were assigned to receive either the four-strain probiotic formulation found in Symprove or a placebo.
Across the intervention period, researchers evaluated a range of outcomes including gut microbiota composition, systemic inflammatory markers and non-motor symptoms associated with Parkinson’s disease.
Participants taking the probiotic formulation showed measurable changes in gut microbiota composition compared with those receiving placebo, including increases in bacterial groups associated with beneficial metabolic activity. The study also reported reductions in markers of systemic inflammation.
Alongside these biological changes, improvements were observed in gastrointestinal symptoms including constipation severity. Participants receiving the probiotic also demonstrated improvements in aspects of fatigue and overall non-motor symptom burden compared with placebo.
While further research is needed to confirm and extend these findings, the study provides early evidence that changes in the gut microbiota may influence inflammation and non-motor symptoms in Parkinson’s disease.
The full published paper is available in Movement Disorders (Leta V, et al. Movement Disorders. 2025;40(12):2710-2721).
About Symprove:
Symprove is the UK's No.1 live and active bacteria supplement*.
Founded in 1986 by Barry Smith, it was created to deliver good bacteria to the gut alive and active. Unlike many powder and capsule probiotics, Symprove's unique water-based formulation is designed to keep its four strains of live bacteria alive so they reach the gut ready to work**.
The brand continues to invest in scientific research, with studies carried out at leading institutions including King's College Hospital, Sheffield Hallam and University College London.
For samples or more information, please get in touch with press@symprove.com.
* UK's No.1 live and active bacteria supplement. Source Euromonitor International Ltd; Consumer Health 2026ed., Symprove retail value sales, UK 2025 data.
**Symprove’s friendly bacteria are proven to reach your gut alive and active based on a validated, in-vitro model (Simulator of the Human Intestinal Microbial Ecosystem; SHIME®) showing 99.3% of bacteria remain viable in gut simulator conditions (Moens et al 2019).